ACADIA Pharmaceuticals
ACAD · NASDAQ
Bulios Fair Price
$15.42
44.0% downside
Current Price
$27.52
According to Bulios Fair Price, ACAD is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
ACADIA Pharmaceuticals Inc. (ACAD) is an American biopharmaceutical company focusing on the development of innovative drugs for the treatment of central nervous system disorders. Their main product, pimavanserin, is an approved medication for the treatment of hallucinations and delusions associated with Parkinson's disease. ACADIA Pharmaceuticals actively engages in clinical trials and research to discover new therapeutic options for patients suffering from neurological disorders. ACADIA Pharmaceuticals Inc. (ACAD) shares could be suitable for investors looking to invest in the biopharmaceutical sector with a focus on innovative treatment approaches for neurological conditions.
Sector
Healthcare
Industry
Biotechnology
CEO
Catherine E. Owen Adams
Employees
797
Headquarters
San Diego
Upcoming events
Earnings
Upcoming earnings report